JP7350337B2 - 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用 - Google Patents

神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用 Download PDF

Info

Publication number
JP7350337B2
JP7350337B2 JP2020517472A JP2020517472A JP7350337B2 JP 7350337 B2 JP7350337 B2 JP 7350337B2 JP 2020517472 A JP2020517472 A JP 2020517472A JP 2020517472 A JP2020517472 A JP 2020517472A JP 7350337 B2 JP7350337 B2 JP 7350337B2
Authority
JP
Japan
Prior art keywords
certain embodiments
alkyl
optionally substituted
occurrence
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535165A5 (https=
JP2020535165A (ja
Inventor
ラヌム，ラウラ
ズー，タオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of JP2020535165A publication Critical patent/JP2020535165A/ja
Publication of JP2020535165A5 publication Critical patent/JP2020535165A5/ja
Application granted granted Critical
Publication of JP7350337B2 publication Critical patent/JP7350337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020517472A 2017-09-26 2018-09-26 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用 Active JP7350337B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563588P 2017-09-26 2017-09-26
US62/563,588 2017-09-26
PCT/US2018/052913 WO2019067587A1 (en) 2017-09-26 2018-09-26 USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS

Publications (3)

Publication Number Publication Date
JP2020535165A JP2020535165A (ja) 2020-12-03
JP2020535165A5 JP2020535165A5 (https=) 2021-11-04
JP7350337B2 true JP7350337B2 (ja) 2023-09-26

Family

ID=65903814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517472A Active JP7350337B2 (ja) 2017-09-26 2018-09-26 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用

Country Status (6)

Country Link
US (2) US11903910B2 (https=)
EP (1) EP3688021A4 (https=)
JP (1) JP7350337B2 (https=)
AU (1) AU2018342105B2 (https=)
CA (1) CA3076214A1 (https=)
WO (1) WO2019067587A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
JP2020535448A (ja) 2017-09-25 2020-12-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Ｒａｎタンパク質の検出のための免役アッセイ
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
US20220267776A1 (en) * 2019-07-05 2022-08-25 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
EP4129293A4 (en) * 2020-03-27 2024-04-03 Kyoto University INHIBITOR OF NERVE CELL DEGENERATION
WO2023102111A1 (en) 2021-12-01 2023-06-08 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
WO2025179209A1 (en) * 2024-02-22 2025-08-28 Whitehead Institute For Biomedical Research Methods and agents to study and restore suppressed protein mobility in disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132982A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
BR9608278A (pt) 1995-04-11 1999-10-13 Merck & Co Inc Processo para produzir um intermediário de dipeptìdeo de um composto à base de dipeptìdeo
WO1999002546A1 (en) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 human secreted proteins
AU751784B2 (en) 1997-08-29 2002-08-29 Innogenetics N.V. Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2407352A1 (en) 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US6846650B2 (en) 2000-10-25 2005-01-25 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
US6855517B2 (en) 2000-11-20 2005-02-15 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
US7163943B2 (en) * 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
WO2005099741A1 (ja) 2004-04-08 2005-10-27 Noevir Co., Ltd. 運動ニューロン疾患治療薬
US20060068434A1 (en) 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
EP1844148A2 (en) 2005-01-31 2007-10-17 University of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
US20090074721A1 (en) 2005-06-06 2009-03-19 Vgx Pharmaceuticals, Inc. Methods for treating viral infection with oral or injectibel drug solution
US20080248099A1 (en) 2005-11-11 2008-10-09 Ishii Douglas N Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin
ES2453374T3 (es) 2006-09-20 2014-04-07 The Queen's University Of Belfast Método para determinar si una célula tumoral presenta potencial invasivo y/o metastásico, y agentes moduladores de la transformación maligna
WO2008097861A2 (en) 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
US20090143418A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of Michigan Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
GB0809821D0 (en) 2008-05-30 2008-07-09 Univ Aberdeen Treatment and diagnosis of behavioural disorders
TW201034684A (en) 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CA2757354A1 (en) 2009-04-02 2010-10-07 Laura P.W. Ranum Nucleotide repeat expansion-associated polypeptides and uses thereof
EP3569254B1 (en) 2009-04-17 2022-07-20 Oxford University Innovation Limited Composition for delivery of genetic material
WO2011028912A2 (en) 2009-09-03 2011-03-10 University Of Tennessee Research Foundation A biomarker for neurodegeneration in neurological disease
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
EP2751284B1 (en) 2011-08-31 2017-01-11 The University Of Manchester Method for diagnosing a neurodegenerative disease.
CN108285491B (zh) 2012-02-29 2021-08-10 桑格摩生物科学股份有限公司 治疗亨廷顿氏病的方法和组合物
KR101417272B1 (ko) 2012-05-15 2014-07-14 경상대학교산학협력단 메트포민 및/또는 타이모퀴논을 포함하는 임신중 알코올 노출에 의한 신경질환 치료 또는 예방용 약학적 조성물
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
PT2948777T (pt) 2013-01-22 2019-09-26 Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V Proteínas de repetição por dipeptídeos como alvo terapêutico em doenças neurodegenerativas com expansão de hexanucleotídico repetido
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
EP2948471A4 (en) 2013-01-24 2016-08-10 Mayo Foundation METHOD AND MATERIALS FOR DETECTING POSITIVE FRONTOTEMPORAL PAPER DEGENERATION BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION OR AMYOTROPHATE LATERAL SCLEROSIS BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
WO2014186746A1 (en) 2013-05-16 2014-11-20 University Of Florida Research Foundation, Inc. HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
EP2837390A1 (en) * 2013-08-15 2015-02-18 Universitäts-Kinderspital beider Basel Combined Pharmaceutical Preparation for Use in Treating Neuromuscular Disorders
WO2016025692A1 (en) 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
WO2016191241A1 (en) 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
JP2019524834A (ja) * 2016-08-18 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ビグアナイド系による発達障害の治療方法
WO2018195110A1 (en) * 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
JP2020535448A (ja) 2017-09-25 2020-12-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Ｒａｎタンパク質の検出のための免役アッセイ
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
US20220267776A1 (en) 2019-07-05 2022-08-25 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132982A1 (en) 2009-05-18 2010-11-25 Ottawa Hospital Research Institute Treatment of muscle disease characterized by insulin resistance

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Gene, 2014, Vol.536, pp.90-96
Nature Medicine，2017年05月15日，Vol.23，pp.674-677
Neuromol. Med., 2016, Vol.18, pp.581-592
Neuroscience Letters, 2007, Vol.411, pp.98-103
PLOS ONE, 2014, Vol.9, No.3, Article No.e90803, pp.1-10

Also Published As

Publication number Publication date
AU2018342105A1 (en) 2020-04-02
AU2018342105B2 (en) 2023-11-16
US20240269093A1 (en) 2024-08-15
US20200268691A1 (en) 2020-08-27
CA3076214A1 (en) 2019-04-04
EP3688021A1 (en) 2020-08-05
JP2020535165A (ja) 2020-12-03
US11903910B2 (en) 2024-02-20
EP3688021A4 (en) 2021-12-29
WO2019067587A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
JP7350337B2 (ja) 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
EP3652329B1 (en) Compounds for tau protein degradation
US11905285B2 (en) Inhibitors of plasma kallikrein and uses thereof
JP2019535759A (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP2019504890A (ja) 選択的エストロゲン受容体分解剤およびその使用
US20250041247A1 (en) Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
US20220064151A1 (en) Activators of class i histone deacetylases (hdacs) and uses thereof
US9695156B2 (en) Compounds for the treatment and prevention of infections
US20170233405A1 (en) Max binders as myc modulators and uses thereof
WO2024233839A1 (en) Small molecule inhibitors of glutaminase
US20230382865A1 (en) Histone demethylase 5 inhibitors and uses thereof
WO2024086705A2 (en) Bicyclic enhancers of the particulate guanylyl cyclase receptor a
US12246021B2 (en) Compounds for uses in pharmacological induction of HBF for treatment of sickle cell disease and ß-thalassemia
WO2024151519A2 (en) Pparg modulators
WO2015057894A1 (en) Methods for treating polycystic kidney disease and polycystic liver disease
HK40008994A (en) Activators of class 1 histone deacetylases (hdacs) and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230906

R150 Certificate of patent or registration of utility model

Ref document number: 7350337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150